Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

INTRODUCTION: In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are prioritised for vaccination. However, data concerning...

Descripción completa

Detalles Bibliográficos
Autores principales: Geisen, Ulf M, Berner, Dennis K, Tran, Florian, Sümbül, Melike, Vullriede, Lena, Ciripoi, Maria, Reid, Hayley M, Schaffarzyk, Annika, Longardt, Ann C, Franzenburg, Jeanette, Hoff, Paula, Schirmer, Jan H, Zeuner, Rainald, Friedrichs, Anette, Steinbach, Andrea, Knies, Christine, Markewitz, Robert DH, Morrison, Peter J, Gerdes, Sascha, Schreiber, Stefan, Hoyer, Bimba F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117443/
https://www.ncbi.nlm.nih.gov/pubmed/33762264
http://dx.doi.org/10.1136/annrheumdis-2021-220272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117443/
https://www.ncbi.nlm.nih.gov/pubmed/33762264
http://dx.doi.org/10.1136/annrheumdis-2021-220272

Ejemplares similares